Author(s): Jesus San-Miguel, Katja Weisel, Gordon Cook, et. al. Abstract: S 101 Session topic: 14. Myeloma and other monoclonal gammopathies – Clinical Background: Daratumumab (D) is a human CD38-targeting monoclonal antibody that exerts its antimyeloma activity through both direct (on-tumor) and indirect (immunomodulatory) mechanisms of action. Two randomized phase 3 trials in...
Pro zobrazení tohoto obsahu je třeba být přihlášen.